TRDA Entrada Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1689375 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-93.5%
TTM net income YoY-56.0%
TTM EPS YoY-49.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-4,303.8%
Net margin-4,058.0%
FCF margin-3,428.1%
EBITDA margin-4,223.6%
Returns
ROE-59.9%
ROA-47.5%
ROIC (approx.)-82.1%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets25.7%
Debt / equity0.00x
Current ratio7.85x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-7.4%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $25.42M | $210.78M |
| R&D expense | $142.27M | $125.31M |
| SG&A expense | $41.05M | $38.47M |
| Operating income | -$157.90M | $47.01M |
| Income tax | $924,000 | $859,000 |
| Net income | -$143.75M | $65.63M |
| EBITDA | -$153.80M | $50.78M |
| EPS (basic) | -3.47 | 1.76 |
| EPS (diluted) | -3.47 | 1.68 |
| Weighted avg. shares (diluted) | 41.37M | 39.00M |
| Balance sheet | ||
| Cash & equivalents | $90.39M | $105.16M |
| Current assets | $306.25M | $440.04M |
| PP&E, net | $7.31M | $10.93M |
| Total assets | $377.38M | $526.32M |
| Current liabilities | $24.45M | $39.48M |
| Total liabilities | $71.25M | $97.64M |
| Shareholders' equity | $306.13M | $428.68M |
| Shares outstanding | 38.28M | 37.57M |
| Cash flow statement | ||
| Operating cash flow | -$128.51M | -$41.56M |
| Capital expenditure | $1.04M | $3.16M |
| Free cash flow | -$129.55M | -$44.72M |
| Investing cash flow | $116.81M | -$27.80M |
| Financing cash flow | $887,000 | $102.96M |
| Depreciation & amortization | $4.10M | $3.77M |
| Stock-based compensation | $19.61M | $17.91M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.